Welcome to STN International! Enter x:x

LOGINID:ssspta1200exs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS
                 "Ask CAS" for self-help around the clock
NEWS
         Apr 08
                 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS
         Apr 09
NEWS
         Apr 09
                 ZDB will be removed from STN
                 US Patent Applications available in IFICDB, IFIPAT, and
         Apr 19
NEWS 5
IFIUDB
NEWS 6
        Apr 22
                Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
NEWS 7
                 BIOSIS Gene Names now available in TOXCENTER
         Apr 22
NEWS 8 Apr 22
                 Federal Research in Progress (FEDRIP) now available
NEWS 9
         Jun 03
                 New e-mail delivery for search results now available
NEWS 10 Jun 10
                MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
                FOREGE no longer contains STANDARDS file segment
NEWS 12 Jul 02
NEWS 13 Jul 22
                USAN to be reloaded July 28, 2002;
                 saved answer sets no longer valid
         Jul 29
NEWS 14
                 Enhanced polymer searching in REGISTRY
NEWS 15
         Jul 30
                 NETFIRST to be removed from STN
NEWS 16
         Aug 08
                 CANCERLIT reload
NEWS 17
                 PHARMAMarketLetter(PHARMAML) - new on STN
         Aug 08
NEWS 18
                 NTIS has been reloaded and enhanced
         Aug 08
NEWS 19
                 Aquatic Toxicity Information Retrieval (AQUIRE)
         Aug 19
                 now available on STN
NEWS 20
         Aug 19
                 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19
                 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26
                 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03
                 JAPIO has been reloaded and enhanced
                Experimental properties added to the REGISTRY file
NEWS 24 Sep 16
                Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 25 Sep 16
NEWS 26 Sep 16
                CA Section Thesaurus available in CAPLUS and CA
NEWS 27
         Oct 01
                CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28
         Oct 21
                 EVENTLINE has been reloaded
NEWS 29
                 BEILSTEIN adds new search fields
         Oct 24
NEWS 30
         Oct 24 Nutraceuticals International (NUTRACEUT) now available on
STN
 NEWS 31
         Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT
NEWS 33 Nov 25 More calculated properties added to REGISTRY
                TIBKAT will be removed from STN
NEWS 34 Dec 02
NEWS 35 Dec 04
                CSA files on STN
NEWS 36 Dec 17
                PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 37 Dec 17 TOXCENTER enhanced with additional content
NEWS 38 Dec 17 Adis Clinical Trials Insight now available on STN
```

NEWS 39 Dec 30 ISMEC no longer available

NEWS EXPRESS December 31 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:27:53 ON 03 JAN 2003

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 08:28:03 ON 03 JAN 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Jan 2003 VOL 138 ISS 2 FILE LAST UPDATED: 2 Jan 2003 (20030102/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```
=> e wo9608485/pn
                   WO9608483/PN
             1
                   WO9608484/PN
E2
E3
             1 --> WO9608485/PN
E4
             1
                   WO9608486/PN
E5
                   WO9608487/PN
             1
                   W09608488/PN
E6
             1
E7
             1
                   W09608489/PN
E.S
             1
                   WO9608490/PN
E9
             1
                   WO9608491/PN
             1
                   W09608492/PN
E10
E11
             1
                   WO9608493/PN
E12
             1
                   W09608494/PN
=> s e3
             1 WO9608485/PN
L1
=> d 11 all
     ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
L1
     1996:428452 CAPLUS
AN
DN
TI
     Preparation of quinoxalinediones as NMDA receptor antagonists
IN
     Mowbray, Charles Eric; Stobie, Alan; Bull, David John; Carr, Christopher
     Lee; Fray, Michael Johnathan
PΑ
     Pfizer Limited, UK; Pfizer Research and Development Company, N.V./s.A.;
     Pfizer Inc.
SO
     PCT Int. Appl., 54 pp.
     CODEN: PIXXD2
DT
     Patent
     English
LΑ
     ICM C07D403-06
ICS A61K031-495
IC
CC
     28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
     Section cross-reference(s): 1
FAN.CNT 1
     PATENT NO.
                     KIND DATE
                                           APPLICATION NO. DATE
PΙ
     WO 9608485
                      A1
                            19960321
                                           WO 1995-EP3483 19950901 <--
         W: CA, FI, JP, MX, US
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     CA 2199845
                       AA
                            19960321
                                          CA 1995-2199845 19950901
     EP 781279
                       Α1
                            19970702
                                           EP 1995-931989
                                                             19950901
     EP 781279
                            20010613
                       В1
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
     JP 09511523
                      T2
                            19971118
                                           JP 1995-509872
                                                             19950901
     JP 2898097
                       B2
                            19990531
     ES 2158126
                       Т3
                            20010901
                                           ES 1995-931989
                                                             19950901
     FI 9701026
                       Α
                            19970312
                                           FI 1997-1026
                                                             19970312
     US 5783572
                                           US 1997-793896
                                                             19970312
                       Α
                            19980721
PRAI GB 1994-18443
                       Α
                            19940913
     WO 1995-EP3483
                      W
                            19950901
OS
     CASREACT 125:86683; MARPAT 125:86683
GΙ
```

$$R^3$$
 X
 H
 R^1
 N
 O
 $C1$
 N
 OMe
 H
 I
 $C1$
 N
 OMe
 N
 OMe

AB The title compds. [I; R1, R2 = F, C1, Br, Me, Et, CF3; R3 = H, Me, Et; X

(substituted) 1,2,4-triazol-1-yl, imidazol-1-yl, pyrazol-1-yl, etc.], useful in the treatment of acute neurodegenerative and chronic neurol. disorders, were prepd. Thus, reaction of quinoxaline II with 1,2,4-triazole in the presence of K2CO3 in AcNMe2 followed by hydrolysis of the intermediate with 2M HCl in dioxane afforded I [R1 = R2 = Cl; R3 = H; X = 1,2,4-triazol-1-yl]. Compds. I are effective at 0.01-1 mg/kg (i.v.).

ST quinoxalinedione NMDA receptor antagonist prepn; nervous system disease degeneration quinoxalinedione prepn; neurotransmitter antagonist quinoxalinedione prepn

IT Neurotransmitter antagonists

(prepn. of quinoxalinediones as NMDA receptor antagonists)

IT Nervous system

(disease, degeneration, treatment; prepn. of quinoxalinediones as NMDA receptor antagonists)

```
IT
     178619-22-2P
                    178619-23-3P
                                    178619-24-4P
                                                    178619-25-5P
                                                                    178619-26-6P
                                                                    178619-31-3P
     178619-27-7P
                     178619-28-8P
                                    178619-29-9P
                                                    178619-30-2P
     178619-32-4P
                     178619-33-5P
                                    178619-34-6P
                                                    178619-35-7P
                                                                    178619-36-8P
     178619-37-9P
                     178619-38-0P
                                    178619-39-1P
                                                    178619-40-4P
                                                                    178619-41-5P
     178619-42-6P
                     178619-43-7P
                                    178619-44-8P
                                                    178619-45-9P
                                                                    178619-46-0P
     178619-47-1P
                    178619-48-2P
                                    178619-49-3P
                                                    178619-50-6P
                                                                    178619-51-7P
     178619-52-8P
                    178619-53-9P
                                    178619-54-0P
                                                    178619-55-1P
                                                                    178619-56-2P
     178619-57-3P
                    178619-58-4P
                                    178619-59-5P
                                                    178619-60-8P
                                                                    178619-61-9P
                    178619-63-1P
     178619-62-0P
                                    178619-64-2P
                                                    178619-65-3P
                                                                    178619-66-4P
     178619-67-5P
                    178619-68-6P
                                    178619-69-7P
                                                    178619-70-0P
                                                                    178619-71-1P
     178619-72-2P
```

RL: BAC (Biological activity or effector, except adverse); BSU Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinoxalinediones as NMDA receptor antagonists)

IT 6384-92-5, NMDA

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(prepn. of quinoxalinediones as NMDA receptor antagonists)

IT 178620-31-0P

RL: BYP (Byproduct); PREP (Preparation)

(prepn. of quinoxalinediones as NMDA receptor antagonists)

IT 75-64-9, reactions 89-69-0, 2,4,5-Trichloronitrobenzene 107-59-5,
 tert-Butyl chloroacetate 109-73-9, n-Butylamine, reactions 110-89-4,
 Piperidine, reactions 110-91-8, Morpholine, reactions 288-32-4,
 Imidazole, reactions 288-88-0, 1H-1,2,4-Triazole 594-39-8
4967-77-5,

```
Methyl 1,2,3-triazole-4-carboxylate
                                           6972-71-0, 4,5-Dimethyl-2-
                    7170-01-6
                                7411-16-7
                                            103433-17-6
    nitroaniline
     153915-05-0
                   178620-30-9
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (prepn. of quinoxalinediones as NMDA receptor antagonists)
                                                                  178619-75-5P
                                                   178619-74-4P
ΙT
     131885-38-6P
                    156349-12-1P
                                   178619-73-3P
                                                   178619-79-9P
                                                                  178619-80-2P
                                   178619-78-8P
     178619-76-6P
                    178619-77-7P
     178619-81-3P
                    178619-82-4P
                                   178619-83-5P
                                                   178619-84-6P
                                                                  178619-85-7P
     178619-86-8P
                    178619-87-9P
                                   178619-88-0P
                                                   178619-89-1P
                                                                  178619-90-4P
                                                   178619-94-8P
                                                                  178619-95-9P
     178619-91-5P
                    178619-92-6P
                                   178619-93-7P
                                   178619-98-2P
                                                   178619-99-3P
                                                                  178620-00-3P
     178619-96-0P
                    178619-97-1P
     178620-01-4P
                    178620-02-5P
                                   178620-03-6P
                                                   178620-04-7P
                                                                  178620-05-8P
     178620-06-9P
                    178620-07-0P
                                   178620-08-1P
                                                   178620-09-2P
                                                                  178620-10-5P
     178620-11-6P
                    178620-12-7P
                                   178620-13-8P
                                                   178620-14-9P
                                                                  178620-15-0P
                                                                  178620-20-7P
                    178620-17-2P
                                                   178620-19-4P
     178620-16-1P
                                   178620-18-3P
                                                   178620-24-1P
     178620-21-8P
                    178620-22-9P
                                   178620-23-0P
                                                                  178620-25-2P
                    178620-27-4P
     178620-26-3P
                                   178620-28-5P
                                                   178620-29-6P
                                                                  178620-32-1P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (prepn. of quinoxalinediones as NMDA receptor antagonists)
```